Ivonescimab Tops Pembrolizumab in PD-L1-Positive, Advanced NSCLC

Published Date: 13 Sep 2024

Novel agent nearly halved risk of progression as first-line therapy in phase III trial

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Beyond What Is Visible in Myelofibrosis?

2.

US Cancer Trials Heavily Favor Single Drugs Over Care Issues

3.

Ivonescimab Tops Pembrolizumab in PD-L1-Positive, Advanced NSCLC

4.

Low Income, Education Tied to Depression in Older Adults

5.

SBRT Plus Atezolizumab Shows No Benefit in Inoperable NSCLC


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot